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Relative lymphocytosis in COVID-19 — a ray of hope
Dear Editor
A recent article on 150 COVID-19 patients 
from Wuhan, China, was a comprehensive analy-
sis of clinical predictors of mortality [1]. Age, 
cardiovascular comorbidities, total leucocyte 
counts, lymphocyte count, platelet count, liver 
and kidney functions, IL-6, C-reactive peptide 
(CRP) and cardiac biomarkers were significantly 
associated with increased mortality. Fulminant 
myocarditis was stressed  as a poor prognostic 
marker. However, an equally important parameter 
is the percentage of lymphocytes. In the same trial 
, total leucocyte count was 10.62 × 109 cells/litre 
vs 6.76 × 109 cells/litre in the dead vs survival 
group, respectively. On the other hand, lymphocy-
topenia was more profound; 0.662 × 109 cells/litre 
in the dead group vs 1.4262 × 109 cells/litre in the 
survival group. Both these values were statistical-
ly significant (p value < 0.05) [1].  
Similarly, in an initial compilation of data 
of 51 COVID-19 patients at the authors’ current 
centre from India, a trend supporting all the above 
observations is  becoming increasingly noticeable. 
The mean leucocyte count was 5.7 × 109 cells/ 
/litre with a mean lymphocyte percent of 40.6% 
(Figure 1, 2). As the mean leucocyte count falls in 
the normal range, this is a relative lymphocytosis, 
defined as increased lymphocyte percent to 40% or 
more [2]. The mean haemoglobin was 16 g/dL and 
platelet count was 260 × 109 per litre. All the pa-
tients had stable vitals, preserved organ functions 
and required only symptomatic treatment for fever 
with or without cough; thereby being classified  as 
having mild upper respiratory tract infection [3].
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Figure 2. The lymphocyte percent is normally distributed with mean 
of 40.6% and a standard deviation of 9.0%
Figure 1. The distribution of total leucocyte count with a mean of 5.7 
× 109 cells/litre
Lymphopenia has been found to be very com-
mon (85%) in critically ill COVID-19 patients [4]. 
Another study tried to develop predictive models, 
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where lymphocyte count > 20% at day 10 of ill-
ness has been found to be  characteristic of the 
moderate group with favourable prognosis [5]. In 
concordance with that, as our mean lymphocyte 
count was 40.6%, all patients were predicted to 
have a recovery.
Multiple mechanisms have been proposed 
for lymphopenia in severe COVID-19. Direct 
lymphocyte inhibition, lymph node destruction, 
inflammatory cytokines, lactic acidosis supres-
sing lymphocytes and coronavirus attaching to 
the angiotensin-converting enzyme 2 (ACE2) 
receptor on lymphocyte are few plausible expla-
nations [4]. However, relative lymphocytosis 
defies all these pathophysiologies and hence may 
be an indication  of a favourable prognosis. Acute 
viral illnesses like varicella, influenza, infectious 
mononucleosis are also associated with relative 
lymphocytosis; most of these eventually develop 
a spontaneous recovery [6]. The mechanism as 
to why some people respond favourably needs 
further research.
This is a very significant observation as a le-
ucocyte count with differential count is done in 
all patients at admission. This, along with other 
predictors like age and comorbidities, can be used 
to make a quick, early decision on the further 
priority and triage, thereby assisting in efficient 
resource allocation. 
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